Zheng (Frank) Zhou, M.D., Ph.D.

(626) 256-4673
Zheng (Frank) Zhou, M.D., Ph.D.
Hematologist-Oncologist
Clinical Expertise
  • Hematology
  • Hematologic Malignancies
  • Hematopoietic Cell Transplantation and Immune Effector Cell Therapy
Research Area
  • Stem cell transplant outcomes research
  • Graft-versus-host disease
  • Leukemia and myeloid malignancies
Other Languages Spoken
Mandarin
Academic Appointments

Assistant Clinical Professor of Medicine, Department of Hematology & Hematopoietic Stem Cell Transplantation

Clinical Teams
Hematology & Hematopoietic Cell Transplantation

"I believe in a patient-centered approach that focuses on providing holistic care whenever possible.”

Zheng (Frank) Zhou, M.D., Ph.D., is a hematologist-oncologist and assistant clinical professor of hematopoietic stem cell transplantation at City of Hope® Cancer Center Duarte, where he brings his expertise in leading-edge cellular therapies, including stem cell transplantation, and his patient-first approach to care to patients with blood cancers and disorders.

After receiving his medical degree at the Shanghai Medical University in China, Dr. Zhou earned a master’s in clinical biochemistry from the University of Newcastle Medical School in the United Kingdom and a Ph.D. in biostatistics and epidemiology at McGill University in Montreal. He completed an internship and residency at the University of Massachusetts Medical School in Worcester and a hematology/oncology clinical fellowship at Northwestern Feinberg School of Medicine in Chicago, where he received the Jameson Research Prize for Outstanding Research Contributions.  

Dr. Zhou has co-authored dozens of peer-reviewed articles and served as principal investigator on a number of research projects focusing on stem cell patient outcomes. He is also actively involved in initiatives sponsored by the Center of International Blood and Marrow Transplantation.

Location

Education & Experience

Degrees

  • 2000-2005, Doctor of Philosophy, Biostatistics and Epidemiology, McGill University, Montreal, Canada
  • 1998-1999, Master of Science, Clinical Biochemistry, University of Newcastle Medical School, Newcastle, United Kingdom
  • 1992-1997, Doctor of Medicine, Shanghai Medical University, Shanghai, China

Fellowship

  • 2011-2014, Hematology and Oncology, Northwestern Memorial Hospital/Northwestern Feinberg School of Medicine, Chicago, Illinois

Internship

  • 2008-2011, Internal Medicine, UMass Memorial Medical Center, University of Massachusetts Medical School, Worcester, Massachusetts

Awards & Memberships

Awards

  • 2020, Physician Champion of Care, Beth Israel Lahey Health, LHMC
  • 2019, Physician Champion of Care, Beth Israel Lahey Health, LHMC
  • 2014, Northwestern Medicine Jameson Research Prize for Outstanding Research Contributions
  • 2013, Illinois Medical Oncology Society Annual Fellow Research Award
  • 2013, ASCO-AACR 2013 Vail Clinical Trial Workshop Selected Attendee and Protocol: A Phase II Study of the Combination of Dabrafenib (BRAF inhibitor) with Cetuximab (anti-EGFR) as Second-line Therapy of BRAF Mutant Metastatic Colon Cancer
  • 2012-2014, National Institute of Health (T32 CA 79447-15) Clinical Fellow Research Training Grant (*Mentors: Jane Winter, MD; Jonathan D. Licht, MD; Steven T. Rosen, MD)
  • 2012, ECOG/ACRIN 12th Annual ECOG/Sanofi-Aventis Oncology Young Investigator Symposium. Selected Presentation and Travel Award
  • 2004, Québec Health Research Foundation (FRSQ), Research Scholarship
  • 2002, Natural Science and Engineering Research Council of Canada (NSERC), Research Scholarship for “Evaluation and Application of Biostatistical Methods in Drug Effectiveness Study Using Computerized Medical Administrative Database”

Memberships

  • American College of Physicians, FACP Elect (2018)
  • American Society of Hematology
  • American Society of Clinical Oncology
  • American Society of Transplantation and Cellular Therapy

Publications

  1. Tracy P, Ruben D, Al-Akdi A, Pilichowska M, and Zhou Z (2025) Extramedullary immunoprivileged sites as a niche for residual and relapsed FLT3-ITD mutated AML: an unmet clinical need. Leukemia and Lymphoma 66 (3): 548-52.
  2. Zhou Z, Nath R, Cerny J, Wang H-L, Zhang M-J, Saber W, et al. (2020) Reduced Intensity Conditioning for Acute Myeloid Leukemia using Melphalan versus Busulfan based Regimens – A CIBMTR Report. Blood Advances 4(13): 3180–90.
  3. Zhou Z, Rademaker A, Gordon LI, LaCasce AS, Crosby-Thompson AL, Vanderplas A, Zelenetz AD, Abel GA, Rodriguez MA, Nademanee AP, Czuczman MS, Kaminski M, Millenson M, Niland J, Friedberg JW, Winter JN (2016) High body mass index in elderly DLBCL patients treated with rituximab containing therapy compensates for negative impact of male sex. JNCCN. 14:1274-81
  4. Zhou Z, Gao J, Popovic R, Wolniak K, Parimi V, Winter, JN, Licht JD and Chen, Y-H (2015) Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma (DLBCL) independent of cell of origin and EZH2 codon 641 mutation. Leukemia and Lymphoma. 56(10):2895-901.
  5. Zhou Z, Sehn L, Rademaker A, Gordon LI, LaCasce AS, Crosby-Thompson AL, Vanderplas A, Zelenetz AD, Abel GA, Czuczman MS, Kaminski M, Millenson M, Nademanee AP, Rodriguez MA, Niland J, Gascoyne RD, Connors JM, Friedberg JW, Winter JN (2014) An enhanced international prognostic index (NCCN-IPI) for patients with diffuse large B cell lymphoma treated in the rituximab era. Blood 123(6): 837-42
  6. Costa LJ, Maddocks K, Epperla N, Reddy NM, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn MJ, Chavez JC, Calzada O, Lansigan F, Nasheed H, Barta SK, Zhou Z, Jaglal M, Chhabra S, Hernandez-Ilizaliturri F, Xavier AC, Mehta A, Peker D, Forero-Torres A, Al-Mansour Z, Evens AM, Cohen JB, Flowers CR, Fenske TS, and Hamadani M (2017). Diffuse large B-cell lymphoma with primary treatment failure: Ultra high-risk features and benchmarking for experimental therapies. American Journal of Hematology 92(2): 161-70.
  7. Trifilo S, Zhou Z, Galvin J, Fong JL, Monreal J and Mehta J. (2015) Filgrastim versus TBO-filgrastim to reduce the duration of neutropenia after autologous hematopoietic stem cell transplantation: TBO, or not TBO, that is the question. Clin Transplant 29:1128-32.
  8. Trifilo S, Zhou Z, Fong J, Zomas T, Kiu D, Zhao C, Zhang J and Mehta J. (2015) Polymicrobial infection: incidence, spectrum of infection, risk factors, and clinical outcomes from a large hematopoietic stem cell transplant center. Transplant Infectious Disease 17(2):267-74.
  9. Taxter T, Zhou Z, Dittmann D, Licht J, Chen YH and Gao J. (2014) A Pyrosequencing assay for the detection of EZH2 Y641 mutations in Diffuse Large B cell Lymphoma and Follicular Lymphoma. Annals of Clinical Pathology 2(4): 1029-34. Page 6 of 8
  10. Trifilio S, Zhou Z, Mehta J, Czerniak C, Pi J, Greenberg D, Koslosky M, Pantiru M, Altman J. (2013) Idarubicin appears equivalent to dose-intense daunorubicin for remission induction in patients with acute myeloid leukemia. Leukemia Research 37(8):868-71

Abstracts

  1. Post-Transplant Cyclophosphamide vs Calcineurin Inhibitor and Methotrexate GVHD Prophylaxis, with or without ATG, in HLA-Matched Donor HSCT in Adults with Hematologic Malignancies Undergoing Reduced Intensity Conditioning: A CIBMTR Analysis of 5,950 Participants. Zhou Z, Wang T, McCurdy SR, Nath R et al. ASBMT/CIBMTR 2026 TCT Meeting (Abstract # 28988), Salt Lake City, UT.
  2. Allogeneic Hematopoietic Stem Cell Transplant in Patients Over Age 70 Years Using Post-Transplant Cyclophosphamide (PTCy) Based Graft Versus Host Disease (GVHD) Prophylaxis: A Single Center Analysis. Nath R, Kodali MK, Kamal A, Ulrickson, ML, Go A, Madan S, Zhou Z. ASBMT/CIBMTR 2023 TCT Meeting (Abstract # 568), Orlando, FL.
  3. Role of Recipient CD34 Specific Chimerism (CSC) in the Bone Marrow (BM) to Predict BM Relapse Post Allogeneic Stem Cell Transplant. Kim A, Zhou Z, Cerny J, Muthalagu R, Raffel GD, Shanahan L, Al-Mansour Z, Yu N and Nath R (2016). ASBMT/CIBMTR 2016 Tandem Meeting (Abstract # 510), Honolulu, HI.
  4. Adequate and Predictable Stem Cell (SC) Collection and Low Incidence of Neutropenic Fever (NF) with Cyclophosphamide (C) and G-CSF Mobilization in Multiple Myeloma (MM): A Single Center Analysis. Patel B, Zhou Z, Appiah J, Raffel GD, Desai Z, Bednarik J, Tessier T, L'Heureux J, Cerny J, Ramanathan M and Nath R (2015). ASBMT/CIBMTR 2015 Tandem Meeting (Abstract # 263), San Diego, CA.
  5. Tbo or Not Tbo - That is the question (2015). Trifilio S, Zhou Z, Fong JI, Galvin JP, Monreal J, Farhan R, Villa M and Mehta J. ASBMT/CIBMTR 2015 Tandem Meeting (Abstract # 365), San Diego, CA.
  6. Immune Recovery (IR) Following Allogeneic Stem Cell Transplant (Allo-SCT): A Comparison of Three Different Transplant Strategies at a Single Transplant Center. Al-Mansour Z, George M, Zhou Z, Raffel GD, Petrillo-Deluca L, Shanahan L, Yu H, Woda BA, Ramanathan M, Cerny J and Nath R. (2015). ASBMT/CIBMTR 2015 Tandem Meeting (Abstract # 205), San Diego, CA.
  7. High Body Mass Index (BMI) in North American Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Rituximab (R)-CHOP Compensates for Negative Impact of Male Gender. Zhou Z, Rademaker AW, Gordon LI, LaCasce AS, Crosby-Thompson AL, Vanderplas A, Abel GA, Rodriguez MA, Nademanee AP, Kaminski M, Czuczman MS, Millenson M, Nilan J, Zelenetz AD, Friedberg JW and Winter J N (2014). ASH 2014 Annual Conference (Abstract #3046), San Francisco, CA.
  8. Unrelated Donor (UD) Cord Blood (CB) Stem Cell Transplantation from a Single CB Unit in Older Adults: Excellent Engraftment and Low Early Mortality with a Preparative Regimen of Melphalan, Thiotepa, Fludarabine, and Rabbit-Anti Thymocyte Globulin (ATG) (2014). Nath R, Ramanathan M, Cerny J, Zhou Z, Raffel, GD, Bednarik J, Yu N, Petrillo-Deluca LJ, A Mansour Z and Zanker D. ASH 2014 Annual Conference (Abstract #1152), San Francisco, CA.
  9. Diagnosis and Management of Polycythemia Vera in the Post-JAK2 V617F Era: A Survey of Practice Patterns. Stein BL, Kander EM, Zhou Z, Streiff MB, Moliterno AR and Spivak JL. (2014). ASH 2014 Annual Conference (Abstract #2172), San Francisco, CA.
  10. Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma (DLBCL) irrespective of germinal center B (GCB) or activated B cell (ABC) type and EZH2 Y641 mutations. Zhou Z, Gao JH, Wolniak K, Parimi V, Winter JN, Licht JD and Chen Y-H (2014) United States and Canadian Academy of Pathology Annual Conference, San Diego, CA.